FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W30491805> ?p ?o ?g. }

• W30491805 endingPage "317" @default.
• W30491805 startingPage "309" @default.
• W30491805 abstract "Background Chronic hepatitis C is common and aggressive in HIV-positive patients, so the development of a well-tolerated HCV therapy is a priority. We evaluated the efficacy and safety of pegylated interferon α2b (PEG-IFN) plus ribavirin (RBV) versus PEG-IFN monotherapy in HIV/HCV-coinfected patients undergoing highly active antiretroviral therapy (HAART), and analysed the predictive factors of response. Methods An Italian, multicentre, open-label trial including 135 coinfected patients, randomized to PEG-IFN 1.5 μg/kg/week plus RBV 400 mg twice daily ( n=69, arm A) or PEG-IFN 1.5 μg/kg/week ( n=66, arm B) for 48 weeks. We assessed the predictive values of early virological response (EVR) at week 8 (HCV-RNA drop >2 log 10 compared with baseline or undetectable levels) on sustained virological response (SVR). Results Fifty-five patients (28 from arm A and 27 from arm B) completed 48 weeks of therapy. At the end of treatment, 20/28 patients in arm A and 11/27 in arm B had HCV-RNA <50 IU/ml. In a per-protocol analysis, SVR was reached by 54% of patients in arm A (genotype 2–3, 11/16; genotype 1–4, 4/12) and 22% in arm B (genotype 2–3, 3/15; genotype 1–4, 3/12). In an intention-to-treat analysis, the SVR was 22% in arm A (genotype 2–3, 11/32; genotype 1–4, 4/37) versus 9% in arm B (genotype 2–3, 3/32; genotype 1–4, 3/34). The best predictors of SVR were the use of combination therapy, infection with HCV genotype 3 versus genotype 1, and EVR at week 8. Thirty patients (15 from arm A and 15 from arm B) dropped out of the trial prematurely due to side effects. The positive predictive value of EVR at week 8 was 65%, the negative predictive value was 86%. Conclusions PEG-IFN plus RBV can be considered a solid option for the treatment of HIV/HCV-coinfected patients. The key to successfully improving efficacy is strong compliance through strict overall patient monitoring, in order to best manage drug toxicity. EVR assessment at week 8 may become a useful stategy in the management of therapy." @default.
• W30491805 created "2016-06-24" @default.
• W30491805 creator A5034720988 @default.
• W30491805 creator A5049157151 @default.
• W30491805 creator A5051247475 @default.
• W30491805 creator A5056509018 @default.
• W30491805 creator A5082623681 @default.
• W30491805 creator A5087788423 @default.
• W30491805 creator A5089728271 @default.
• W30491805 date "2005-02-01" @default.
• W30491805 modified "2023-10-11" @default.
• W30491805 title "Open, Randomized, Multicentre Italian Trial on Peg-Ifn plus Ribavirin versus Peg-Ifn Monotherapy for Chronic Hepatitis C in HIV-Coinfected Patients on Haart" @default.
• W30491805 cites W1971648486 @default.
• W30491805 cites W1992239172 @default.
• W30491805 cites W1993484328 @default.
• W30491805 cites W1996434966 @default.
• W30491805 cites W2000674705 @default.
• W30491805 cites W2005933189 @default.
• W30491805 cites W2017960775 @default.
• W30491805 cites W2027545702 @default.
• W30491805 cites W2034482023 @default.
• W30491805 cites W2082729322 @default.
• W30491805 cites W2085691878 @default.
• W30491805 cites W2092795242 @default.
• W30491805 cites W2094883696 @default.
• W30491805 cites W2102371310 @default.
• W30491805 cites W2103529803 @default.
• W30491805 cites W2103638317 @default.
• W30491805 cites W2106762291 @default.
• W30491805 cites W2112876622 @default.
• W30491805 cites W2121595515 @default.
• W30491805 cites W2122764811 @default.
• W30491805 cites W2127685726 @default.
• W30491805 cites W2138244980 @default.
• W30491805 cites W2146970203 @default.
• W30491805 cites W2311319609 @default.
• W30491805 cites W4255524937 @default.
• W30491805 cites W96201458 @default.
• W30491805 doi "https://doi.org/10.1177/135965350501000215" @default.
• W30491805 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15865225" @default.
• W30491805 hasPublicationYear "2005" @default.
• W30491805 type Work @default.
• W30491805 sameAs 30491805 @default.
• W30491805 citedByCount "31" @default.
• W30491805 countsByYear W304918052012 @default.
• W30491805 countsByYear W304918052014 @default.
• W30491805 countsByYear W304918052015 @default.
• W30491805 countsByYear W304918052016 @default.
• W30491805 crossrefType "journal-article" @default.
• W30491805 hasAuthorship W30491805A5034720988 @default.
• W30491805 hasAuthorship W30491805A5049157151 @default.
• W30491805 hasAuthorship W30491805A5051247475 @default.
• W30491805 hasAuthorship W30491805A5056509018 @default.
• W30491805 hasAuthorship W30491805A5082623681 @default.
• W30491805 hasAuthorship W30491805A5087788423 @default.
• W30491805 hasAuthorship W30491805A5089728271 @default.
• W30491805 hasBestOaLocation W304918051 @default.
• W30491805 hasConcept C104317684 @default.
• W30491805 hasConcept C126322002 @default.
• W30491805 hasConcept C135763542 @default.
• W30491805 hasConcept C168563851 @default.
• W30491805 hasConcept C203014093 @default.
• W30491805 hasConcept C2522874641 @default.
• W30491805 hasConcept C2776408679 @default.
• W30491805 hasConcept C2776455275 @default.
• W30491805 hasConcept C2776461080 @default.
• W30491805 hasConcept C2780040827 @default.
• W30491805 hasConcept C55493867 @default.
• W30491805 hasConcept C71924100 @default.
• W30491805 hasConcept C86803240 @default.
• W30491805 hasConcept C90924648 @default.
• W30491805 hasConceptScore W30491805C104317684 @default.
• W30491805 hasConceptScore W30491805C126322002 @default.
• W30491805 hasConceptScore W30491805C135763542 @default.
• W30491805 hasConceptScore W30491805C168563851 @default.
• W30491805 hasConceptScore W30491805C203014093 @default.
• W30491805 hasConceptScore W30491805C2522874641 @default.
• W30491805 hasConceptScore W30491805C2776408679 @default.
• W30491805 hasConceptScore W30491805C2776455275 @default.
• W30491805 hasConceptScore W30491805C2776461080 @default.
• W30491805 hasConceptScore W30491805C2780040827 @default.
• W30491805 hasConceptScore W30491805C55493867 @default.
• W30491805 hasConceptScore W30491805C71924100 @default.
• W30491805 hasConceptScore W30491805C86803240 @default.
• W30491805 hasConceptScore W30491805C90924648 @default.
• W30491805 hasIssue "2" @default.
• W30491805 hasLocation W304918051 @default.
• W30491805 hasLocation W304918052 @default.
• W30491805 hasOpenAccess W30491805 @default.
• W30491805 hasPrimaryLocation W304918051 @default.
• W30491805 hasRelatedWork W2004479501 @default.
• W30491805 hasRelatedWork W2009634266 @default.
• W30491805 hasRelatedWork W2055190024 @default.
• W30491805 hasRelatedWork W2067034737 @default.
• W30491805 hasRelatedWork W2078888723 @default.
• W30491805 hasRelatedWork W2108648362 @default.
• W30491805 hasRelatedWork W2318824964 @default.
• W30491805 hasRelatedWork W2321188506 @default.

• next